Search

Managing Side Effects of Anti-VEGF Bevacizumab & Anti-EGFR Cetuximab and Panitumumab


 

Keypoints: 

Pashtoon-Kasi-OC-W

•⁠  ⁠Overview of Bevacizumab and its side effects, including hypertension, proteinuria, and risk of bleeding.
•⁠  ⁠Clinical pearls for managing side effects associated with Bevacizumab.
•⁠  ⁠Discussion on the skin toxicities, nail changes, and electrolyte imbalances related to Panitumumab and Cetuximab.
•⁠  ⁠The importance of preemptive strategies in managing skin rashes and other side effects.
•⁠  ⁠Insights into infusion reactions with Cetuximab and considerations for patient safety.

In this episode of the Oncology Brothers podcast, we had the pleasure of welcoming Dr. Pashtoon Kasi from City of Hope to discuss the management of side effects associated with key treatments in metastatic colorectal cancer and other tumor types, specifically focusing on two important drug classes: anti-VEGF, Bevacizumab and the anti-EGFR antibodies, Pentatumumab and Cetuximab.

We began by establishing a foundational understanding of these targeted therapies. Dr. Kasi emphasized that these biologic agents are not traditional chemotherapies; rather, they focus on unique aspects of the cancer or the tumor microenvironment. This distinction is crucial for understanding their side effects and management strategies.

Diving into Bevacizumab, we explored common side effects such as hypertension, proteinuria, and the risks of bleeding and thrombosis. Dr. Kasi shared valuable clinical pearls, including the importance of communication among healthcare providers and the need for careful monitoring, especially regarding blood pressure and potential surgical interventions.

We then transitioned to Panitumumab, discussing its skin toxicities and the importance of preemptive strategies to manage these side effects effectively. Dr. Kasi highlighted the significance of addressing skin rashes early on, as they can severely impact a patient's quality of life. He also recommended involving dermatologists in the care process to optimize management.

Lastly, we touched on Cetuximab, noting the potential for infusion-related reactions and the geographic considerations that may influence its use. Dr. Kasi provided insights into dosing strategies and the importance of monitoring for electrolyte imbalances, particularly hypomagnesemia, which can arise with anti-EGFR therapies.

Overall, this episode served as a reminder of the critical role we play in managing the side effects of these therapies to improve patient outcomes and quality of life. We hope our listeners find these discussions helpful as they navigate the complexities of oncology care.

Thank you for tuning in, and be sure to check out our other episodes on antibody drug conjugates (ADCs) and CAR-T therapies.